Fifteen Industry Leaders Unite to Advance CGT Industrial Upgrading at Shenzhen Weiguang Life Science Park & Bay Gravity

"Cutting-Edge Technologies Accelerate the R&D of Cell and Gene Therapy"

"Through precise gene editing, avoid mutation risks and accelerate scientific progress."

"Preparation and Evaluation of Animal Disease Models"

"Golden Quote: 'We use animal models to reproduce diseases, paving new ways for health research.'"

Overview of the CAR-T Industry in Cell Therapy

Golden Sentence: "Twenty-six years of dedication to chromatography separation technology, with craftsmanship for peace of mind."

"In our cooperation with clients, we have discovered that the needs of the party A are changing. From initially pursuing speed to now placing more emphasis on the quality and innovation of cooperation. As a CDMO, Yuanxing Gene has assisted more than ten domestic products in advancing to different clinical stages, always keeping up with the industry's forefront and maintaining an attitude of learning and innovation. In terms of serum-free process amplification for gene therapy viral vectors and pursuing lower residuals, Yuanxing has formed its unique advantages in quality."

In fact, innovation is everywhere, and there are opportunities to think creatively at every turn. As a CDMO company, we rely on two words—experience! We need to think one step ahead of our clients, act faster, more steadily, and cost-effectively. We must also excel in scaling and regulatory understanding. In today’s industry, new processes are emerging constantly. The key lies in interacting with our clients, building trust, and jointly addressing the challenges posed by immature processes. Trust is the cornerstone; without it, cooperation becomes a lose-lose game.

"In the current environment, most of our clients' demands revolve around achieving more with less spending. However, we believe that low cost should not be the sole focus; sharing risks and benefits is the way to ensure long-term success. Our approach is to work closely with clients in the early stages to negotiate pricing for our culture media and consumables, with the hope that once their product succeeds — such as reaching Phase III clinical trials or going to market — we can continue our partnership and create a win-win situation. This is not just business; it’s about building trust and fostering mutual growth."

"Danahe's innovation is reflected in how to integrate existing resources to form different solutions to meet customer demands. We not only utilize current equipment and technology but also consider future potential needs. For example, in the field of cell therapy, there are over 800 registered CAR-T clinical trial projects globally, with more than 400 from China. To further accelerate this process, we have developed spatial omics solutions using technologies such as spatial transcriptomics and multiplex immunofluorescence to identify specific prognostic markers. These markers play a crucial role in optimizing clinical cohorts and expediting FDA approval processes. This can accelerate the entire translational process and help customers bring their products to market faster."

"When it comes to technical services, we have a basketful of experiences with pitfalls. Behind every animal model, there are stories and lessons. Having encountered numerous challenges, we have naturally accumulated rich experience and served a large number of clients. The first value of Top Biotech is integrity. New employees must understand from the start that scientific research integrity is paramount. We do not falsify; we emphasize high-quality interactions, which has earned us our reputation and allowed us to establish ourselves in the market for the long term."

"Our corporate values focus on two aspects. The first is comprehensiveness, which refers to a full-scale layout, providing customers with one-stop services from early-stage process development to later industrial-scale production. The second is sincerity—treating our customers with genuine care. If a customer directly contacts our leadership due to issues with our products, we would be pleased because it shows they trust us. Over the years, user feedback has helped us improve significantly, especially in terms of intelligence and adapting to new application scenarios. We are able to respond quickly and provide users with stable and reliable separation and purification equipment."

"Innovation is often discussed, but it is not limited to significant breakthroughs in scientific principles; it should have a broader meaning. Identifying application scenarios, improving efficiency and effectiveness, monitoring and reducing risks are also forms of innovation, without blindly pursuing novelty. Innovation must also fully consider practicality. For example, the pursuit of automation and digitalization levels requires each company to assess whether it is suitable for their current stage, evaluate the input-output ratio and return on investment, and conduct specific analyses based on actual needs."

"I think the most important question is how our project can be transformed into a product that attracts attention and favor from the industry and investors? The role of the technology transfer department in research institutions is like a bridge, which requires versatile talents with various experiences to help basic research scientists explore the application potential of their findings, promote cooperation with translational researchers, and connect scientific research, clinical practice, the industrial sector, and funding parties to transform scientific achievements into innovative products that meet clinical needs."

"Because I am engaged in basic scientific research, I most want to understand what kind of data is needed to move forward with translation. For example, if we want to work on CAR-T, we’ve conducted some cellular experiments, and the animal experiments seem effective, but not all projects that appear effective can move on to clinical trials or IND. So, what exactly needs to be achieved for a project to be valuable and advance in the clinical direction? This is the question many people in basic research want to understand the most."

"The Translational Medicine Center of Shenzhen Bay Laboratory has gathered a group of talents with experience in the overseas pharmaceutical industry. From project initiation to the identification of hit compounds, lead compounds, and preclinical candidate compounds (PCC), all processes adhere to the standards of the pharmaceutical industry, with some plans advancing to IND. Additionally, the center collaborates with academia to develop innovative first-in-class drugs targeting novel pathways. We also look forward to partnering with the pharmaceutical industry to co-develop our drug pipeline or leverage the center’s ultra-high throughput small molecule and antibody platforms to jointly create new drug pipelines with pharmaceutical companies."

"Our country has a strong source of innovation, with Chinese scientists contributing many brilliant ideas and technologies, but the challenge lies in the transformation. How to turn laboratory achievements into real productive forces is the key issue we face. In the biopharmaceutical industry, despite the impressive publication records, truly innovative drugs are still rare in the industrial pipeline. The establishment of translational medicine centers aimed to replicate the American model, using foundation investments to push early-stage projects to the PCC or IND stage before selling them to large pharmaceutical companies, and then reinvesting the proceeds into further research and development. However, upon returning to China, it became clear that this process is not easily implemented domestically. This may require us to explore our own transformation pathways suited to national conditions—just as historical innovation theories needed localization strategies when they were applied in China."

"I have observed a cycle in the industry: professors wonder why good technologies are not adopted clinically, clinical experts can achieve results but fail to gain regulatory approval, and regulators, in turn, question whether the research is sufficient. In our pharmaceuticals industry, there are two very critical points: regulatory compliance and value demonstration. At the current stage of development, these aspects lack in-depth discussion. Pharmaceutical companies, research institutes, and research teams involved in product development should actively build communication bridges with clinicians and regulators, understand the latest industry trends, adapt to the dynamic development of regulations, and strengthen adjustments for compatibility."

"In this complex systems engineering, we are well aware that every step may encounter challenges, but the key lies in whether we have unique insights to interpret past failures and what makes our approach different. Building on a solid scientific foundation, we strive to avoid known pitfalls while pursuing innovation, ensuring that our technology can truly solve problems. Moreover, we never work in isolation; we maintain an open attitude, seeking complementary partners to jointly drive the project forward."

"Clinical needs are not equivalent to medical needs. For example, the rapid at-home genetic testing service that delivers results within three hours—I believe this is an example of creating something that meets the needs of ordinary people. What we need to do is create more such solutions to address practical issues on the clinical side. At the same time, as an upstream raw material supplier, providing stable materials that meet regulatory requirements, supporting our clients in producing accessible products for the public, and gaining a deeper understanding of our clients' products to facilitate information exchange—this allows innovative achievements to better connect with the market, gain policy and financial support, and drive the true implementation of scientific research outcomes."

"At VectorBuilder, we not only provide services but also hope to leverage the nearly 20 years of experience in translating scientific research into industrial applications by our founder, Dr. Lantian Lan, and the team. We know how to collaborate with researchers at every stage, from small-scale experiments to clinical-grade production, through collaborative innovation to advance the transformation of projects towards industrialization. Our strength lies in our deep scientific foundation, serving over 4,500 research institutions and pharmaceutical R&D departments across more than 90 countries worldwide. From research concepts to production processes, we can precisely align and serve our clients, striving to be the bridge connecting scientific dreams with industrial reality."

"When considering how to support early-stage academic research and biotech startups, there are several key strategies to keep in mind. The core mission of a company lies in establishing a long-term, mutually beneficial value exchange mechanism, which not only genuinely meets the needs of partners but also provides the company with steady revenue, ensuring the realization of commercial value. Shenzhen Shenyan Biological Technology Co., LTD is highly willing to expand and deepen collaborations with these early-stage projects and explore what specific value can be provided during the early phases of research. The key to finding the right partner lies in initiating proactive and candid dialogues, using language that both parties understand to clearly present their respective values and expectations. This communication approach is equally applicable when collaborating with enterprises, investors, and even government institutions."

"I think as a company, we need to look inward for our own survival capability. On one hand, cash is tight for everyone right now, and if financing falls through, companies still need to preserve their strength and focus on their cash flow— it needs to be at least healthy and not break. Once the cash flow breaks, you lose your qualification to stay in the game. On the other hand, I believe we must have core competitiveness, a differentiated technological advantage. It doesn't matter if we move slower; preserve strength because the market will come back within a year or two."

"Financing is not easy these days. In my opinion, if you have money, take it first—whether it’s 10 million or 20 million, cherish it all. The environment is tough, and advancing a project itself is already significant progress; every step forward is an opportunity. China has a vast market and technological potential. Even in the current climate, I believe great opportunities are embedded within crises, especially in the field of cancer treatment vaccines. We focus on solving real-world problems, particularly treatments for cancer patients. As long as the project can genuinely help patients, it will naturally attract investors’ attention."

"I think investors may pay a lot of attention to data, prospects, clinical efficacy, and another aspect might be more about commercial value. However, I place greater emphasis on long-term goals: making expensive treatments more affordable by reducing prices to an acceptable range, while also selecting broad indications to expand the audience base and enhance commercial potential."

"In the current unfavorable capital environment, we must firmly believe that the cell and gene industry is one of the important directions for the development of biopharmaceuticals both in China and internationally. We need to stay true to our original mission, focus on core source technologies and product development, proactively lower valuations, and seek diversified cooperation. As long as we find a reliable team, I believe valuation is not the main issue at present. The most important thing is to find excellent partners, including industrial funds or large pharmaceutical companies. As long as we share common values, survive, and work together, sooner or later, we will see spring arrive."

"In the industry winter, we must learn to be self-reliant, take charge early, and streamline our pipelines and R&D projects based on our core competitiveness, making efficient use of resources. In difficult times, it is even more important to look inward, maintain technological leadership, and seek external cooperation to jointly mitigate risks. This way, even in a market downturn, we can stabilize our position and wait patiently for opportunities."

"This year, the investment criteria of various investment institutions have become more stringent, which also drives us to explore truly innovative potential. Remember, focus on a single breakthrough point, concentrate resources to refine premium products— even in a small market, a top position can bring opportunities. As for going global, understand buyers' mindsets: safety, efficacy, and patents are indispensable, while flexibility and forward-looking strategies are equally crucial."

"As a state-owned enterprise, we tend to be more conservative, pursuing returns under the premise of controllable risks. In terms of investment strategy, we prefer projects that can show results in the short term or have already been verified with clear efficacy. As for the trick, it’s actually quite simple: sincere communication, more exchanges, stockpiling good projects, and waiting for the right opportunity. When the market is down, it’s even more important to stay grounded, avoid storytelling, secure funding legally and compliantly—amount is not the only factor; quality is key."

"Currently, CGT remains a key focus due to its unique advantages and rapid validation potential. In the context of a tightening market, we have become more cautious, placing higher demands on project quality and preferring in-depth data discussions to understand the underlying significance rather than rushing into decisions. Our approach is to patiently wait for the optimal entry point, grow together with project teams, and ensure every step is solid and reliable."

Shenzhen Shenyan Biological Technology Co., LTD has been seeking investors and partners who have confidence in the cell and gene therapy (CGT) industry, believe in technological innovation, and align with the company's vision. Because they need to share risks together, they focus more on long-term value rather than just price.

In the decade-long development journey of Shenzhen Shenyan Biological Technology Co., LTD, a sense of mission has been their driving force to keep moving forward in adversity. During the financing process, sincerity and pragmatism are crucial. There is no such thing as a perfect entrepreneurial team; "hexagon warriors" are extremely rare. Shenyan Biotech has also been facing its own shortcomings head-on, candidly presenting the challenges and pain points the company encounters. Investors are not only investing in an industry or a company but, to a large extent, they are also investing in people — the members of this entrepreneurial team.